Loperamide

CHEMBL841 Phase 4 Onaylandı Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
477.0 g/mol
LogP
5.0
Phase
4

An opioid receptor agonist acting locally in the gut, used to treat diarrhea including traveler's diarrhea and diarrhea associated with inflammatory bowel disease. It slows intestinal motility and reduces fluid loss without crossing the blood-brain barrier in therapeutic doses.

Moleküler Ağırlık

477,0000 g/mol

LogP

5,00

TPSA

43,80 Ų

Lipinski RO5

Geçer

Terapötik Alanlar

Etki Mekanizması

Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.

2D Yapı

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1

InChI

InChI=1S/C29H33ClN2O2/c1-31(2)27(33)29(24-9-5-3-6-10-24,25-11-7-4-8-12-25)19-22-32-20-17-28(34,18-21-32)23-13-15-26(30)16-14-23/h3-16,34H,17-22H2,1-2H3

Molecular Formula

C29H33ClN2O2

HBD / HBA

1 / 3

Döndürülebilir Bağlar

7

Ağır Atomlar

34

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

An opioid receptor agonist acting locally in the gut, used to treat diarrhea including traveler's diarrhea and diarrhea associated with inflammatory bowel disease. It slows intestinal motility and reduces fluid loss without crossing the blood-brain barrier in therapeutic doses.

Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.

Yes, Loperamide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL841. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3955. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.